Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lindsey Beffa

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Oncotarget|June 6, 2019
Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genesNicole E James, Lindsey Beffa, Matthew T Oliver, et al.
Journal of Genetic Counseling|April 27, 2021
Family planning in carriers of BRCA1 and BRCA2 pathogenic variantsJessica M Haddad, Katina Robison, Lindsey Beffa, et al.
Surgical Endoscopy|August 28, 2023
Physiologic tension of the abdominal wallBenjamin T Miller, Ryan C Ellis, R Matthew Walsh, et al.
Menopause (New York, N.Y.)|May 16, 2023
Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriersJessica B DiSilvestro, Jessica Haddad, Katina Robison, et al.
Journal of Women'S Health (2002)|March 15, 2024
Ovarian Cancer Risk-Reduction and Screening in <i>BRCA1/2</i> Mutation CarriersJessica B DiSilvestro, Jessica Haddad, Katina Robison, et al.
Scientific Reports|May 24, 2020
The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genesNicole E James, Jenna B Emerson, Ashley D Borgstadt, et al.
The New England Journal of Medicine|March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Nature Medicine|March 5, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trialRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Oncotarget|June 6, 2019
Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genesNicole E James, Lindsey Beffa, Matthew T Oliver, et al.
Journal of Genetic Counseling|April 27, 2021
Family planning in carriers of BRCA1 and BRCA2 pathogenic variantsJessica M Haddad, Katina Robison, Lindsey Beffa, et al.
Surgical Endoscopy|August 28, 2023
Physiologic tension of the abdominal wallBenjamin T Miller, Ryan C Ellis, R Matthew Walsh, et al.
Menopause (New York, N.Y.)|May 16, 2023
Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriersJessica B DiSilvestro, Jessica Haddad, Katina Robison, et al.
Journal of Women'S Health (2002)|March 15, 2024
Ovarian Cancer Risk-Reduction and Screening in <i>BRCA1/2</i> Mutation CarriersJessica B DiSilvestro, Jessica Haddad, Katina Robison, et al.
Scientific Reports|May 24, 2020
The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genesNicole E James, Jenna B Emerson, Ashley D Borgstadt, et al.
The New England Journal of Medicine|March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Nature Medicine|March 5, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trialRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Pageof 2